This meta-analysis evaluated the 4 new oral anticoagulants and compared their efficacy and side-effects to those of warfarin using results from randomized trials of treatment of afib. Outcomes in nearly 72,000 recipients were evaluated, including stroke, embolic events, mortality, MI, and bleeding. The newer anticoagulants reduced stroke risk by 19
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.